^
Association details:
| Biomarker: | BCL2L1 overexpression |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
EX VIVO DRUG TESTING HIGHLIGHTS APOPTOSIS PATHWAYS AS TARGETS IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Published date:
05/14/2020
Excerpt:
BCL2 expression was significantly higher in PhnegALL patients, whereas PhposALL had significantly higher expression of BCL-W, and a trend to higher BCL-XL expression. Thus, poorer venetoclax efficacy in PhposALL ex vivo is correlated to higher dependency on BCL-W and BCL-XL. In addition, cysteinyl leukotriene receptor 1 (CYSLTR1) expression was significantly higher in PhposALL samples (Figure 1).
